GLOBAL OPTHALMOLOGY DRUGS AND DEVICES MARKET FORECAST 2018-2026
KEY FINDINGS
The global ophthalmic drugs and device market is expected to grow at a CAGR of 5.97% over the forecast period of 2018-2026. The rising eye-related disorders in the world, changing lifestyle, and rising healthcare expenditure are the major driving factors in the growth of the global ophthalmic drug and devices market.
MARKET INSIGHTS
The global ophthalmic drugs and devices market is segmented on the basis of the type of devices and type of drugs. The devices are sub-segmented into diagnostic and monitoring equipments, surgery devices, and vision care devices. The drugs segment of the market includes glaucoma drugs, retinal disorder drug, dry eye drug, inflammation, allergic conjunctivitis, and conjunctivitis drugs and drugs by use of preservation. Well-known drugs are going off patent, and key players affected by the delay in new drugs coming into the market are the two factors restricting the growth of the market. The market faces challenges in risk associated with the ocular diseases and lack of awareness among people regarding ophthalmology.
REGIONAL INSIGHTS
Geographically, the global ophthalmic drugs & devices market is segmented into North America, Europe, Asia-Pacific, and Rest of World. Currently, North America holds a massive market share followed by Europe and Asia-Pacific. Due to rising geriatric population, increase in strategic initiatives by large market players present in the region and increasing prevalence of ocular diseases, the North America ophthalmic drugs & devices market holds high growth prospects for the near future. However, over the forecasted period, the Asia-Pacific market is expected to grow with the highest CAGR. APAC market is majorly driven by the rising prevalence and increasing facilities for eye treatment in hospitals.
COMPETITIVE INSIGHTS
Allergan Inc, Bayer, Carl Zeiss Ag, Essilor International S.A, GlaxoSmithKline, Johnson & Johnson Inc, Novartis International Ag, Pfizer, Roche Holding Ag, Santen Pharmaceutical Co Ltd, Sun Pharmaceuticals Industries Ltd, Valent Pharmaceuticals International Inc and Ziemer Group Holding Ag are few of the noted companies in the global ophthalmology drugs and devices market.
The global ophthalmic drugs and device market is expected to grow at a CAGR of 5.97% over the forecast period of 2018-2026. The rising eye-related disorders in the world, changing lifestyle, and rising healthcare expenditure are the major driving factors in the growth of the global ophthalmic drug and devices market.
MARKET INSIGHTS
The global ophthalmic drugs and devices market is segmented on the basis of the type of devices and type of drugs. The devices are sub-segmented into diagnostic and monitoring equipments, surgery devices, and vision care devices. The drugs segment of the market includes glaucoma drugs, retinal disorder drug, dry eye drug, inflammation, allergic conjunctivitis, and conjunctivitis drugs and drugs by use of preservation. Well-known drugs are going off patent, and key players affected by the delay in new drugs coming into the market are the two factors restricting the growth of the market. The market faces challenges in risk associated with the ocular diseases and lack of awareness among people regarding ophthalmology.
REGIONAL INSIGHTS
Geographically, the global ophthalmic drugs & devices market is segmented into North America, Europe, Asia-Pacific, and Rest of World. Currently, North America holds a massive market share followed by Europe and Asia-Pacific. Due to rising geriatric population, increase in strategic initiatives by large market players present in the region and increasing prevalence of ocular diseases, the North America ophthalmic drugs & devices market holds high growth prospects for the near future. However, over the forecasted period, the Asia-Pacific market is expected to grow with the highest CAGR. APAC market is majorly driven by the rising prevalence and increasing facilities for eye treatment in hospitals.
COMPETITIVE INSIGHTS
Allergan Inc, Bayer, Carl Zeiss Ag, Essilor International S.A, GlaxoSmithKline, Johnson & Johnson Inc, Novartis International Ag, Pfizer, Roche Holding Ag, Santen Pharmaceutical Co Ltd, Sun Pharmaceuticals Industries Ltd, Valent Pharmaceuticals International Inc and Ziemer Group Holding Ag are few of the noted companies in the global ophthalmology drugs and devices market.
1. RESEARCH SCOPE
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
3.2. KEY FINDINGS
3.2.1. VISION CARE DEVICES ARE DOMINATING THE MARKET
3.2.2. NORTH AMERICA IS THE MARKET LEADER
3.2.3. GLAUCOMA DRUGS ARE MAJORLY USED
3.2.4. RISING PREVALENCE OF EYE RELATED DISEASES
4. MARKET DETERMINANTS
4.1. MARKET DRIVERS
4.1.1. GLOBAL INCREASE IN PREVALENCE RATES OF EYE DISEASES
4.1.2. INCREASING PREVALENCE OF DIABETES INCREASES PROBABILITY OF OPHTHALMIC DISORDERS
4.1.3. INCREASING GERIATRIC POPULATION GLOBALLY
4.1.4. TECHNOLOGICAL ADVANCEMENT
4.1.5. INCREASE IN HEALTHCARE EXPENDITURE
4.2. MARKET RESTRAINTS
4.2.1. RENOWNED DRUGS GOING OFF-PATENT
4.2.2. DELAY IN DRUG APPROVALS
4.2.3. AWARENESS RELATED TO OPHTHALMOLOGY DRUGS ARE LOW
4.3. MARKET OPPORTUNITIES
4.3.1. INCREASE IN DISORDER SYMPTOM AND IMPROVED DIAGNOSIS LEADING TO HIGHER TREATMENT RATES
4.3.2. GROWING OPPORTUNITIES IN DEVELOPING ECONOMIES
4.3.3. INCREASING DEMAND FOR INTRAOCULAR LENSES AND PHACOEMULSIFICATION DEVICES
4.4. MARKET CHALLENGES
4.4.1. SLOW GROWTH IN THE DOMESTIC ECONOMY
4.4.2. VARIOUS RISK AND COMPLICATIONS ASSOCIATED WITH THE TREATMENT OF OCULAR DISEASES
5. MARKET SEGMENTATION
5.1. MARKET BY DRUGS AND DEVICES 2018-2026
5.1.1. DEVICES
5.1.1.1. DIAGNOSTIC & MONITORING EQUIPMENT
5.1.1.1.1. OPTICAL COHERENCE TOMOGRAPHY
5.1.1.1.2. OPHTHALMIC ULTRASOUND IMAGING SYSTEMS
5.1.1.1.3. FUNDUS CAMERA MARKET
5.1.1.1.4. OPHTHALMOSCOPES
5.1.1.1.5. RETINOSCOPE
5.1.1.1.6. PACHYMETER
5.1.1.1.7. WAVEFRONT ABERROMETERS
5.1.1.1.8. PERIMETERS/VISUAL FIELD ANALYZER
5.1.1.1.9. AUTOREFRACTORS/PHOROPTER
5.1.1.1.10. SPECULAR MICROSCOPE
5.1.1.1.11. CORNEAL TOPOGRAPHERS
5.1.1.1.12. OTHER DIAGNOSTIC & MONITORING EQUIPMENT MARKET
5.1.1.2. SURGERY DEVICE
5.1.1.2.1. CATARACT SURGERY DEVICES
5.1.1.2.2. GLAUCOMA SURGERY DEVICES
5.1.1.2.3. REFRACTIVE SURGERY DEVICES
5.1.1.2.4. VITREORETINAL SURGERY DEVICES
5.1.1.3. VISION CARE
5.1.2. DRUGS
5.1.2.1. GLAUCOMA DRUG
5.1.2.2. RETINAL DISORDER DRUG
5.1.2.3. DRY EYE DRUG
5.1.2.4. ALLERGIC CONJUNCTIVITIS, INFLAMMATION AND CONJUNCTIVITIS DRUG
5.1.2.5. DRUGS BY USE OF PRESERVATION
5.1.2.5.1. PRESERVED DRUGS
5.1.2.5.2. PRESERVATIVE FREE DRUGS
6. KEY ANALYTICS
6.1. PORTER’S FIVE FORCES ANALYSIS
6.1.1. BARGAINING POWER OF BUYERS
6.1.2. BARGAINING POWER OF SUPPLIER
6.1.3. THREATS OF NEW ENTRANTS
6.1.4. THREATS OF SUBSTITUTES
6.1.5. COMPETITIVE RIVALRY
6.2. VALUE CHAIN ANALYSIS
6.2.1. RESEARCH AND DEVELOPMENT
6.2.2. MANUFACTURING
6.2.3. DISTRIBUTORS
6.2.4. END USERS
6.3. STRATEGIC ANALYSIS
6.4. KEY BUYING CRITERIA
6.4.1. COST
6.4.2. EFFICACY
6.4.3. ACCESSIBILITY
6.4.4. INNOVATION
6.5. SUPPLY CHAIN ANALYSIS
6.5.1. SUPPLIERS
6.5.2. MANUFACTURERS
6.5.3. DISTRIBUTORS AND RETAILERS
6.5.4. END USERS
6.6. REGULATORY FRAMEWORK
6.7. ESTIMATION ANALYSIS
6.8. PARENT MARKET ANALYSIS
6.9. INVESTMENT ANALYSIS
7. GEOGRAPHICAL ANALYSIS
7.1. NORTH AMERICA
7.1.1. THE UNITED STATES
7.1.2. CANADA
7.2. EUROPE
7.2.1. THE UK
7.2.2. FRANCE
7.2.3. GERMANY
7.2.4. SPAIN
7.2.5. ITALY
7.2.6. REST OF EUROPE
7.3. ASIA PACIFIC
7.3.1. INDIA
7.3.2. CHINA
7.3.3. JAPAN
7.3.4. SOUTH KOREA
7.3.5. AUSTRALIA
7.3.6. REST OF APAC
7.4. REST OF WORLD
7.4.1. LATIN AMERICA
7.4.2. MIDDLE EAST AND NORTH AFRICA (MENA)
7.4.3. REST OF AFRICA
8. COMPANY PROFILES
8.1. COMPETITIVE ANALYSIS
8.1.1. MARKET SHARE ANALYSIS
8.1.2. TOP COMPANIES
8.1.2.1. ESSILOR INTERNATIONAL S.A. (FRANCE)
8.1.2.2. JOHNSON & JOHNSON INC. (U.S.)
8.1.2.3. ALLERGAN PLC (U.S.)
8.1.2.4. NOVARTIS INTERNATIONAL AG (SWITZERLAND)
8.1.2.5. VALENT PHARMACEUTICALS INTERNATIONAL INC. (U.S.)
8.2. ALLERGAN INC.
8.2.1. COMPANY OVERVIEW
8.2.2. PRODUCT & SERVICES
8.2.3. SWOT ANALYSIS
8.2.4. STRATEGIC INITIATIVES
8.3. BAYER
8.3.1. COMPANY OVERVIEW
8.3.2. PRODUCT & SERVICES
8.3.3. SWOT ANALYSIS
8.3.4. STRATEGIC INITIATIVES
8.4. CARL ZEISS AG
8.4.1. COMPANY OVERVIEW
8.4.2. PRODUCT PORTFOLIO
8.4.3. SWOT ANALYSIS
8.4.4. STRATEGIC INITIATIVE
8.5. ESSILOR INTERNATIONAL S.A.
8.5.1. COMPANY OVERVIEW
8.5.2. PRODUCT & SERVICES
8.5.3. SWOT ANALYSIS
8.5.4. STRATEGIC INITIATIVE
8.6. GLAXOSMITHKLINE
8.6.1. COMPANY OVERVIEW
8.6.2. PRODUCT PORTFOLIO
8.6.3. SWOT ANALYSIS
8.7. JOHNSON & JOHNSON INC.
8.7.1. COMPANY OVERVIEW
8.7.2. PRODUCT PORTFOLIO
8.7.3. SCOT ANALYSIS
8.7.4. STRATEGIC INITIATIVES
8.8. NOVARTIS INTERNATIONAL AG
8.8.1. COMPANY OVERVIEW
8.8.2. PRODUCT PORTFOLIO
8.8.3. SCOT ANALYSIS
8.8.4. STRATEGIC INITIATIVES
8.9. PFIZER
8.9.1. COMPANY OVERVIEW
8.9.2. PRODUCT PORTFOLIO
8.9.3. SCOT ANALYSIS
8.9.4. STRATEGIC INITIATIVES
8.10. ROCHE HOLDING AG
8.10.1. COMPANY OVERVIEW
8.10.2. PRODUCT PORTFOLIO
8.10.3. SCOT ANALYSIS
8.10.4. STRATEGIC INITIATIVES
8.11. SANTEN PHARMACEUTICAL CO., LTD.
8.11.1. COMPANY OVERVIEW
8.11.2. PRODUCT PORTFOLIO
8.11.3. SCOT ANALYSIS
8.11.4. STRATEGIC INITIATIVE
8.12. SUN PHARMACEUTICALS INDUSTRIES, LTD
8.12.1. COMPANY OVERVIEW
8.12.2. PRODUCT PORTFOLIO
8.12.3. SCOT ANALYSIS
8.12.4. STRATEGIC INITIATIVE
8.13. VALENT PHARMACEUTICALS INTERNATIONAL INC.
8.13.1. COMPANY OVERVIEW
8.13.2. PRODUCT PORTFOLIO
8.13.3. SCOT ANALYSIS
8.13.4. STRATEGIC INITIATIVE
8.14. ZIEMER GROUP HOLDING AG
8.14.1. COMPANY OVERVIEW
8.14.2. PRODUCT PORTFOLIO
8.14.3. SCOT ANALYSIS
8.14.4. STRATEGIC INITIATIVE
TABLE LIST
TABLE 1 GLOBAL OPTHALMOLOGY DRUGS AND DEVICES MARKET BY GEOGRAPHY 2018-2026
TABLE 2 PREVALENCE OF EYE DISEASES IN US 2014 & 2030
TABLE 3 NUMBER OF CATARACT SURGERIES UNDER GLOBAL ACTION PLAN 2014-2019 (GAP)
TABLE 4 COMMON CAUSES OF LOSS OF VISION IN THE ELDERLY
TABLE 5 SELECTED LIST OF GLAUCOMA DRUGS IN LATE-STAGE CLINICAL TRIALS
TABLE 6 EYE DRUGS GONE OFF-PATENT
TABLE 7 GLOBAL OPTHALMOLOGY DRUGS AND DEVICES MARKET BY DRUGS AND DEVICES 2018-2026 ($ MILLION)
TABLE 8 GLOBAL DRUGS AND DEVICES MARKET IN DEVICES 2018-2026 ($ MILLION)
TABLE 9 GLOBAL DEVICES MARKET IN DIAGNOSTIC & MONITORING EQUIPMENT BY TYPES 2018-2026 ($ MILLION)
TABLE 10 GLOBAL DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN OPTICAL COHERENCE TOMOGRAPHY BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 11 GLOBAL DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN OPHTHALMIC ULTRASOUND IMAGING SYSTEMS BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 12 GLOBAL DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN FUNDUS CAMERA MARKET BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 13 GLOBAL DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN OPHTHALMOSCOPES BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 14 GLOBAL DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN RETINOSCOPE BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 15 GLOBAL DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN PACHYMETER BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 16 GLOBAL DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN WAVEFRONT ABERROMETERS BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 17 GLOBAL DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN PERIMETERS/VISUAL FIELD ANALYZER BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 18 GLOBAL DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN AUTOREFRACTORS/PHOROPTER BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 19 GLOBAL DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN SPECULAR MICROSCOPE BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 20 GLOBAL DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN CORNEAL TOPOGRAPHERS BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 21 GLOBAL DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN OTHER DIAGNOSTIC & MONITORING EQUIPMENT MARKET BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 22 GLOBAL DEVICES MARKET IN SURGERY DEVICE BY TYPES 2018-2026 ($ MILLION)
TABLE 23 GLOBAL SURGERY DEVICES MARKET IN CATARACT SURGERY DEVICES BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 24 GLOBAL SURGERY DEVICES MARKET IN GLAUCOMA SURGERY DEVICES BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 25 GLOBAL SURGERY DEVICES MARKET IN REFRACTIVE SURGERY DEVICES BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 26 GLOBAL SURGERY DEVICES MARKET IN VITREORETINAL SURGERY DEVICES BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 27 GLOBAL DEVICES MARKET IN VISION CARE MARKET BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 28 GLOBAL DRUGS AND DEVICES MARKET IN DRUGS BY TYPES 2018-2026 ($ MILLION)
TABLE 29 GLOBAL DRUGS MARKET IN GLAUCOMA DRUG BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 30 GLOBAL DRUGS MARKET IN RETINAL DISORDER DRUG BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 31 GLOBAL DRUGS MARKET IN DRY EYE DRUG BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 32 GLOBAL DRUGS MARKET IN ALLERGIC CONJUNCTIVITIS, INFLAMMATION AND CONJUNCTIVITIS DRUG BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 33 GLOBAL DRUGS MARKET IN DRUGS BY USE OF PRESERVATION 2018-2026 ($ MILLION)
TABLE 34 GLOBAL DRUGS BY USE OF PRESERVATION IN PRESERVATIVE FREE DRUGS BY DOSES 2018-2026 ($ MILLION)
TABLE 35 GLOBAL DRUGS BY USE OF PRESERVATION IN PRESERVATIVE FREE DRUGS 2018-2026 ($ MILLION)
TABLE 36 GLOBAL OPTHALMOLOGY DRUGS AND DEVICES MARKET BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 37 NORTH AMERICA OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
TABLE 38 EUROPE OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
TABLE 39 ASIA PACIFIC OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
TABLE 40 REST OF WORLD OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
FIGURE LIST
FIGURE 1 GLOBAL OPTHALMOLOGY DRUGS AND DEVICES MARKET BY GEOGRAPHY 2018-2026
FIGURE 2 PREVALENCE OF DIABETES BY AGE GROUP (MILLIONS)
FIGURE 3 THE POPULATION OF PEOPLE AGED 65 AND OVER WILL DOUBLE IN THE NEXT 25 YEARS (IN MILLIONS)
FIGURE 4 PROJECTIONS FOR THE PROPORTION OF GERIATRIC (60+) POPULATION IN 2015, 2030 & 2050
FIGURE 5 GLOBAL DRUGS AND DEVICES MARKET IN DEVICES 2018-2026 ($ MILLION)
FIGURE 6 GLOBAL DEVICES MARKET DIAGNOSTIC & MONITORING EQUIPMENT IN 2018-2026 ($ MILLION)
FIGURE 7 GLOBAL DEVICES MARKET IN SURGERY DEVICE 2018-2026 ($ MILLION)
FIGURE 8 GLOBAL DEVICES MARKET IN VISION CARE MARKET 2018-2026 ($ MILLION)
FIGURE 9 GLOBAL DRUGS AND DEVICES MARKET IN DRUGS 2018-2026 ($ MILLION)
FIGURE 10 GLOBAL DRUGS MARKET IN GLAUCOMA DRUG 2018-2026 ($ MILLION)
FIGURE 11 GLOBAL DRUGS MARKET IN RETINAL DISORDER DRUG 2018-2026 ($ MILLION)
FIGURE 12 GLOBAL DRUGS MARKET IN DRY EYE DRUG 2018-2026 ($ MILLION)
FIGURE 13 GLOBAL DRUGS MARKET IN ALLERGIC CONJUNCTIVITIS, INFLAMMATION AND CONJUNCTIVITIS DRUG 2018-2026 ($ MILLION)
FIGURE 14 GLOBAL DRUGS BY USE OF PRESERVATION IN PRESERVED DRUGS 2018-2026 ($ MILLION)
FIGURE 15 GLOBAL PRESERVED FREE DRUGS MARKET IN SINGLE-DOSE 2018-2026 ($ MILLION)
FIGURE 16 GLOBAL PRESERVED FREE DRUGS MARKET IN MULTI-DOSE 2018-2026 ($ MILLION)
FIGURE 17 NUMBER OF POPULATION WITH DIABETES 2015 & 2040 (IN MILLION)
FIGURE 18 NORTH AMERICA OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
FIGURE 19 THE UNITED STATES OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
FIGURE 20 CANADA OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
FIGURE 21 EUROPE OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
FIGURE 22 THE UK OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
FIGURE 23 FRANCE OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
FIGURE 24 GERMANY OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
FIGURE 25 SPAIN OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
FIGURE 26 ITALY OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
FIGURE 27 REST OF EUROPE OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
FIGURE 28 ASIA PACIFIC OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
FIGURE 29 INDIA OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
FIGURE 30 CHINA OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
FIGURE 31 JAPAN OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
FIGURE 32 SOUTH KOREA OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
FIGURE 33 AUSTRALIA OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
FIGURE 34 REST OF APAC OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
FIGURE 35 REST OF WORLD OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
FIGURE 36 LATIN AMERICA OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
FIGURE 37 MENA OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
FIGURE 38 REST OF AFRICA OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
FIGURE 39 GLOBAL OPHTHALMOLOGY DEVICES COMPANY MARKET SHARE 2017 (%)
FIGURE 40 GLOBAL OPHTHALMOLOGY DRUGS COMPANY MARKET SHARE 2017 (%)
COMPANIES MENTIONED
2. ALLERGAN INC.
3. BAYER
4. CARL ZEISS AG
5. ESSILOR INTERNATIONAL S.A.
6. GLAXOSMITHKLINE
7. JOHNSON & JOHNSON INC.
8. NOVARTIS INTERNATIONAL AG
9. PFIZER
10. ROCHE HOLDING AG
11. SANTEN PHARMACEUTICAL CO., LTD.
12. SUN PHARMACEUTICALS INDUSTRIES, LTD
13. VALENT PHARMACEUTICALS INTERNATIONAL INC.
14. ZIEMER GROUP HOLDING AG
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
3.2. KEY FINDINGS
3.2.1. VISION CARE DEVICES ARE DOMINATING THE MARKET
3.2.2. NORTH AMERICA IS THE MARKET LEADER
3.2.3. GLAUCOMA DRUGS ARE MAJORLY USED
3.2.4. RISING PREVALENCE OF EYE RELATED DISEASES
4. MARKET DETERMINANTS
4.1. MARKET DRIVERS
4.1.1. GLOBAL INCREASE IN PREVALENCE RATES OF EYE DISEASES
4.1.2. INCREASING PREVALENCE OF DIABETES INCREASES PROBABILITY OF OPHTHALMIC DISORDERS
4.1.3. INCREASING GERIATRIC POPULATION GLOBALLY
4.1.4. TECHNOLOGICAL ADVANCEMENT
4.1.5. INCREASE IN HEALTHCARE EXPENDITURE
4.2. MARKET RESTRAINTS
4.2.1. RENOWNED DRUGS GOING OFF-PATENT
4.2.2. DELAY IN DRUG APPROVALS
4.2.3. AWARENESS RELATED TO OPHTHALMOLOGY DRUGS ARE LOW
4.3. MARKET OPPORTUNITIES
4.3.1. INCREASE IN DISORDER SYMPTOM AND IMPROVED DIAGNOSIS LEADING TO HIGHER TREATMENT RATES
4.3.2. GROWING OPPORTUNITIES IN DEVELOPING ECONOMIES
4.3.3. INCREASING DEMAND FOR INTRAOCULAR LENSES AND PHACOEMULSIFICATION DEVICES
4.4. MARKET CHALLENGES
4.4.1. SLOW GROWTH IN THE DOMESTIC ECONOMY
4.4.2. VARIOUS RISK AND COMPLICATIONS ASSOCIATED WITH THE TREATMENT OF OCULAR DISEASES
5. MARKET SEGMENTATION
5.1. MARKET BY DRUGS AND DEVICES 2018-2026
5.1.1. DEVICES
5.1.1.1. DIAGNOSTIC & MONITORING EQUIPMENT
5.1.1.1.1. OPTICAL COHERENCE TOMOGRAPHY
5.1.1.1.2. OPHTHALMIC ULTRASOUND IMAGING SYSTEMS
5.1.1.1.3. FUNDUS CAMERA MARKET
5.1.1.1.4. OPHTHALMOSCOPES
5.1.1.1.5. RETINOSCOPE
5.1.1.1.6. PACHYMETER
5.1.1.1.7. WAVEFRONT ABERROMETERS
5.1.1.1.8. PERIMETERS/VISUAL FIELD ANALYZER
5.1.1.1.9. AUTOREFRACTORS/PHOROPTER
5.1.1.1.10. SPECULAR MICROSCOPE
5.1.1.1.11. CORNEAL TOPOGRAPHERS
5.1.1.1.12. OTHER DIAGNOSTIC & MONITORING EQUIPMENT MARKET
5.1.1.2. SURGERY DEVICE
5.1.1.2.1. CATARACT SURGERY DEVICES
5.1.1.2.2. GLAUCOMA SURGERY DEVICES
5.1.1.2.3. REFRACTIVE SURGERY DEVICES
5.1.1.2.4. VITREORETINAL SURGERY DEVICES
5.1.1.3. VISION CARE
5.1.2. DRUGS
5.1.2.1. GLAUCOMA DRUG
5.1.2.2. RETINAL DISORDER DRUG
5.1.2.3. DRY EYE DRUG
5.1.2.4. ALLERGIC CONJUNCTIVITIS, INFLAMMATION AND CONJUNCTIVITIS DRUG
5.1.2.5. DRUGS BY USE OF PRESERVATION
5.1.2.5.1. PRESERVED DRUGS
5.1.2.5.2. PRESERVATIVE FREE DRUGS
6. KEY ANALYTICS
6.1. PORTER’S FIVE FORCES ANALYSIS
6.1.1. BARGAINING POWER OF BUYERS
6.1.2. BARGAINING POWER OF SUPPLIER
6.1.3. THREATS OF NEW ENTRANTS
6.1.4. THREATS OF SUBSTITUTES
6.1.5. COMPETITIVE RIVALRY
6.2. VALUE CHAIN ANALYSIS
6.2.1. RESEARCH AND DEVELOPMENT
6.2.2. MANUFACTURING
6.2.3. DISTRIBUTORS
6.2.4. END USERS
6.3. STRATEGIC ANALYSIS
6.4. KEY BUYING CRITERIA
6.4.1. COST
6.4.2. EFFICACY
6.4.3. ACCESSIBILITY
6.4.4. INNOVATION
6.5. SUPPLY CHAIN ANALYSIS
6.5.1. SUPPLIERS
6.5.2. MANUFACTURERS
6.5.3. DISTRIBUTORS AND RETAILERS
6.5.4. END USERS
6.6. REGULATORY FRAMEWORK
6.7. ESTIMATION ANALYSIS
6.8. PARENT MARKET ANALYSIS
6.9. INVESTMENT ANALYSIS
7. GEOGRAPHICAL ANALYSIS
7.1. NORTH AMERICA
7.1.1. THE UNITED STATES
7.1.2. CANADA
7.2. EUROPE
7.2.1. THE UK
7.2.2. FRANCE
7.2.3. GERMANY
7.2.4. SPAIN
7.2.5. ITALY
7.2.6. REST OF EUROPE
7.3. ASIA PACIFIC
7.3.1. INDIA
7.3.2. CHINA
7.3.3. JAPAN
7.3.4. SOUTH KOREA
7.3.5. AUSTRALIA
7.3.6. REST OF APAC
7.4. REST OF WORLD
7.4.1. LATIN AMERICA
7.4.2. MIDDLE EAST AND NORTH AFRICA (MENA)
7.4.3. REST OF AFRICA
8. COMPANY PROFILES
8.1. COMPETITIVE ANALYSIS
8.1.1. MARKET SHARE ANALYSIS
8.1.2. TOP COMPANIES
8.1.2.1. ESSILOR INTERNATIONAL S.A. (FRANCE)
8.1.2.2. JOHNSON & JOHNSON INC. (U.S.)
8.1.2.3. ALLERGAN PLC (U.S.)
8.1.2.4. NOVARTIS INTERNATIONAL AG (SWITZERLAND)
8.1.2.5. VALENT PHARMACEUTICALS INTERNATIONAL INC. (U.S.)
8.2. ALLERGAN INC.
8.2.1. COMPANY OVERVIEW
8.2.2. PRODUCT & SERVICES
8.2.3. SWOT ANALYSIS
8.2.4. STRATEGIC INITIATIVES
8.3. BAYER
8.3.1. COMPANY OVERVIEW
8.3.2. PRODUCT & SERVICES
8.3.3. SWOT ANALYSIS
8.3.4. STRATEGIC INITIATIVES
8.4. CARL ZEISS AG
8.4.1. COMPANY OVERVIEW
8.4.2. PRODUCT PORTFOLIO
8.4.3. SWOT ANALYSIS
8.4.4. STRATEGIC INITIATIVE
8.5. ESSILOR INTERNATIONAL S.A.
8.5.1. COMPANY OVERVIEW
8.5.2. PRODUCT & SERVICES
8.5.3. SWOT ANALYSIS
8.5.4. STRATEGIC INITIATIVE
8.6. GLAXOSMITHKLINE
8.6.1. COMPANY OVERVIEW
8.6.2. PRODUCT PORTFOLIO
8.6.3. SWOT ANALYSIS
8.7. JOHNSON & JOHNSON INC.
8.7.1. COMPANY OVERVIEW
8.7.2. PRODUCT PORTFOLIO
8.7.3. SCOT ANALYSIS
8.7.4. STRATEGIC INITIATIVES
8.8. NOVARTIS INTERNATIONAL AG
8.8.1. COMPANY OVERVIEW
8.8.2. PRODUCT PORTFOLIO
8.8.3. SCOT ANALYSIS
8.8.4. STRATEGIC INITIATIVES
8.9. PFIZER
8.9.1. COMPANY OVERVIEW
8.9.2. PRODUCT PORTFOLIO
8.9.3. SCOT ANALYSIS
8.9.4. STRATEGIC INITIATIVES
8.10. ROCHE HOLDING AG
8.10.1. COMPANY OVERVIEW
8.10.2. PRODUCT PORTFOLIO
8.10.3. SCOT ANALYSIS
8.10.4. STRATEGIC INITIATIVES
8.11. SANTEN PHARMACEUTICAL CO., LTD.
8.11.1. COMPANY OVERVIEW
8.11.2. PRODUCT PORTFOLIO
8.11.3. SCOT ANALYSIS
8.11.4. STRATEGIC INITIATIVE
8.12. SUN PHARMACEUTICALS INDUSTRIES, LTD
8.12.1. COMPANY OVERVIEW
8.12.2. PRODUCT PORTFOLIO
8.12.3. SCOT ANALYSIS
8.12.4. STRATEGIC INITIATIVE
8.13. VALENT PHARMACEUTICALS INTERNATIONAL INC.
8.13.1. COMPANY OVERVIEW
8.13.2. PRODUCT PORTFOLIO
8.13.3. SCOT ANALYSIS
8.13.4. STRATEGIC INITIATIVE
8.14. ZIEMER GROUP HOLDING AG
8.14.1. COMPANY OVERVIEW
8.14.2. PRODUCT PORTFOLIO
8.14.3. SCOT ANALYSIS
8.14.4. STRATEGIC INITIATIVE
TABLE LIST
TABLE 1 GLOBAL OPTHALMOLOGY DRUGS AND DEVICES MARKET BY GEOGRAPHY 2018-2026
TABLE 2 PREVALENCE OF EYE DISEASES IN US 2014 & 2030
TABLE 3 NUMBER OF CATARACT SURGERIES UNDER GLOBAL ACTION PLAN 2014-2019 (GAP)
TABLE 4 COMMON CAUSES OF LOSS OF VISION IN THE ELDERLY
TABLE 5 SELECTED LIST OF GLAUCOMA DRUGS IN LATE-STAGE CLINICAL TRIALS
TABLE 6 EYE DRUGS GONE OFF-PATENT
TABLE 7 GLOBAL OPTHALMOLOGY DRUGS AND DEVICES MARKET BY DRUGS AND DEVICES 2018-2026 ($ MILLION)
TABLE 8 GLOBAL DRUGS AND DEVICES MARKET IN DEVICES 2018-2026 ($ MILLION)
TABLE 9 GLOBAL DEVICES MARKET IN DIAGNOSTIC & MONITORING EQUIPMENT BY TYPES 2018-2026 ($ MILLION)
TABLE 10 GLOBAL DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN OPTICAL COHERENCE TOMOGRAPHY BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 11 GLOBAL DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN OPHTHALMIC ULTRASOUND IMAGING SYSTEMS BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 12 GLOBAL DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN FUNDUS CAMERA MARKET BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 13 GLOBAL DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN OPHTHALMOSCOPES BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 14 GLOBAL DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN RETINOSCOPE BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 15 GLOBAL DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN PACHYMETER BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 16 GLOBAL DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN WAVEFRONT ABERROMETERS BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 17 GLOBAL DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN PERIMETERS/VISUAL FIELD ANALYZER BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 18 GLOBAL DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN AUTOREFRACTORS/PHOROPTER BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 19 GLOBAL DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN SPECULAR MICROSCOPE BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 20 GLOBAL DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN CORNEAL TOPOGRAPHERS BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 21 GLOBAL DIAGNOSTIC & MONITORING EQUIPMENT MARKET IN OTHER DIAGNOSTIC & MONITORING EQUIPMENT MARKET BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 22 GLOBAL DEVICES MARKET IN SURGERY DEVICE BY TYPES 2018-2026 ($ MILLION)
TABLE 23 GLOBAL SURGERY DEVICES MARKET IN CATARACT SURGERY DEVICES BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 24 GLOBAL SURGERY DEVICES MARKET IN GLAUCOMA SURGERY DEVICES BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 25 GLOBAL SURGERY DEVICES MARKET IN REFRACTIVE SURGERY DEVICES BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 26 GLOBAL SURGERY DEVICES MARKET IN VITREORETINAL SURGERY DEVICES BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 27 GLOBAL DEVICES MARKET IN VISION CARE MARKET BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 28 GLOBAL DRUGS AND DEVICES MARKET IN DRUGS BY TYPES 2018-2026 ($ MILLION)
TABLE 29 GLOBAL DRUGS MARKET IN GLAUCOMA DRUG BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 30 GLOBAL DRUGS MARKET IN RETINAL DISORDER DRUG BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 31 GLOBAL DRUGS MARKET IN DRY EYE DRUG BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 32 GLOBAL DRUGS MARKET IN ALLERGIC CONJUNCTIVITIS, INFLAMMATION AND CONJUNCTIVITIS DRUG BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 33 GLOBAL DRUGS MARKET IN DRUGS BY USE OF PRESERVATION 2018-2026 ($ MILLION)
TABLE 34 GLOBAL DRUGS BY USE OF PRESERVATION IN PRESERVATIVE FREE DRUGS BY DOSES 2018-2026 ($ MILLION)
TABLE 35 GLOBAL DRUGS BY USE OF PRESERVATION IN PRESERVATIVE FREE DRUGS 2018-2026 ($ MILLION)
TABLE 36 GLOBAL OPTHALMOLOGY DRUGS AND DEVICES MARKET BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 37 NORTH AMERICA OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
TABLE 38 EUROPE OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
TABLE 39 ASIA PACIFIC OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
TABLE 40 REST OF WORLD OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
FIGURE LIST
FIGURE 1 GLOBAL OPTHALMOLOGY DRUGS AND DEVICES MARKET BY GEOGRAPHY 2018-2026
FIGURE 2 PREVALENCE OF DIABETES BY AGE GROUP (MILLIONS)
FIGURE 3 THE POPULATION OF PEOPLE AGED 65 AND OVER WILL DOUBLE IN THE NEXT 25 YEARS (IN MILLIONS)
FIGURE 4 PROJECTIONS FOR THE PROPORTION OF GERIATRIC (60+) POPULATION IN 2015, 2030 & 2050
FIGURE 5 GLOBAL DRUGS AND DEVICES MARKET IN DEVICES 2018-2026 ($ MILLION)
FIGURE 6 GLOBAL DEVICES MARKET DIAGNOSTIC & MONITORING EQUIPMENT IN 2018-2026 ($ MILLION)
FIGURE 7 GLOBAL DEVICES MARKET IN SURGERY DEVICE 2018-2026 ($ MILLION)
FIGURE 8 GLOBAL DEVICES MARKET IN VISION CARE MARKET 2018-2026 ($ MILLION)
FIGURE 9 GLOBAL DRUGS AND DEVICES MARKET IN DRUGS 2018-2026 ($ MILLION)
FIGURE 10 GLOBAL DRUGS MARKET IN GLAUCOMA DRUG 2018-2026 ($ MILLION)
FIGURE 11 GLOBAL DRUGS MARKET IN RETINAL DISORDER DRUG 2018-2026 ($ MILLION)
FIGURE 12 GLOBAL DRUGS MARKET IN DRY EYE DRUG 2018-2026 ($ MILLION)
FIGURE 13 GLOBAL DRUGS MARKET IN ALLERGIC CONJUNCTIVITIS, INFLAMMATION AND CONJUNCTIVITIS DRUG 2018-2026 ($ MILLION)
FIGURE 14 GLOBAL DRUGS BY USE OF PRESERVATION IN PRESERVED DRUGS 2018-2026 ($ MILLION)
FIGURE 15 GLOBAL PRESERVED FREE DRUGS MARKET IN SINGLE-DOSE 2018-2026 ($ MILLION)
FIGURE 16 GLOBAL PRESERVED FREE DRUGS MARKET IN MULTI-DOSE 2018-2026 ($ MILLION)
FIGURE 17 NUMBER OF POPULATION WITH DIABETES 2015 & 2040 (IN MILLION)
FIGURE 18 NORTH AMERICA OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
FIGURE 19 THE UNITED STATES OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
FIGURE 20 CANADA OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
FIGURE 21 EUROPE OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
FIGURE 22 THE UK OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
FIGURE 23 FRANCE OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
FIGURE 24 GERMANY OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
FIGURE 25 SPAIN OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
FIGURE 26 ITALY OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
FIGURE 27 REST OF EUROPE OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
FIGURE 28 ASIA PACIFIC OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
FIGURE 29 INDIA OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
FIGURE 30 CHINA OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
FIGURE 31 JAPAN OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
FIGURE 32 SOUTH KOREA OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
FIGURE 33 AUSTRALIA OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
FIGURE 34 REST OF APAC OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
FIGURE 35 REST OF WORLD OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
FIGURE 36 LATIN AMERICA OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
FIGURE 37 MENA OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
FIGURE 38 REST OF AFRICA OPTHALMOLOGY DRUGS AND DEVICES MARKET 2018-2026 ($ MILLION)
FIGURE 39 GLOBAL OPHTHALMOLOGY DEVICES COMPANY MARKET SHARE 2017 (%)
FIGURE 40 GLOBAL OPHTHALMOLOGY DRUGS COMPANY MARKET SHARE 2017 (%)
COMPANIES MENTIONED
2. ALLERGAN INC.
3. BAYER
4. CARL ZEISS AG
5. ESSILOR INTERNATIONAL S.A.
6. GLAXOSMITHKLINE
7. JOHNSON & JOHNSON INC.
8. NOVARTIS INTERNATIONAL AG
9. PFIZER
10. ROCHE HOLDING AG
11. SANTEN PHARMACEUTICAL CO., LTD.
12. SUN PHARMACEUTICALS INDUSTRIES, LTD
13. VALENT PHARMACEUTICALS INTERNATIONAL INC.
14. ZIEMER GROUP HOLDING AG
